J&J Medical Connect
VELETRI®

(epoprostenol)

J&J Medical Connect

Connect with us

  • Products

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

VELETRI® (epoprostenol)
Medical Information

Sensitivity of VELETRI to Light in an Extension Line

Last Updated: 08/20/2026

CLINICAL DATA

In a study that was performed to measure the stability of VELETRI for injection at different temperatures following dilution to various concentrations of epoprostenol, experimental samples were not shielded from light.1

Additionally, during the studies EPITOME-12 and EPITOME-23 comparing the administration of epoprostenol sodium for injection (e.g., Flolan®) and VELETRI for injection in patients with PAH, light-sensitive lines were not used.2-4

Direct exposure to sunlight may lead to warming of the VELETRI for injection solution and consequently, a negative impact on product potency. For this reason, VELETRI for injection solutions should be shielded from direct sunlight.5

Literature Search

A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, DERWENT® (and/or other resources, including internal/external databases) was conducted on 02 March 2026.

References

Show
1 Lambert O, Bandilla D. Stability and preservation of a new formulation of epoprostenol sodium for treatment of pulmonary arterial hypertension. Drug Des Devel Ther. 2012;6((Suppl. 23049244)):235-244.  
2 Chin KM, Badesch DB, Robbins IM, et al. Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study. Am Heart J. 2014;167(2):218-225.e1.  
3 Sitbon O, Delcroix M, Bergot E, et al. EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension. Am Heart J. 2014;167(2):210-217.  
4 Data on File. Epoprostenol. AC-066A401/402 Clinical Study Report (EPITOME-1) and AC-066A301 Clinical Study Report (EPITOME-2). Janssen Scientific Affairs, LLC; 2021.  
5 Epoprostenol. Company Core Data Sheet. Janssen Scientific Affairs, LLC. EDMS-ERI-205912254. 2021.  

Would you like to clear and leave your conversation? Message history will be lost.